LY305
Legal status | |
---|---|
Legal status |
|
Identifiers | |
IUPAC name
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
ChEMBL | |
Chemical and physical data | |
Formula | C14H17ClN2O2 |
Molar mass | 280.75 g·mol−1 |
3D model (JSmol) | |
SMILES
| |
InChI
|
LY305 is a transdermally bioavailable selective androgen receptor modulator (SARM) developed by Eli Lilly for the treatment of osteoporosis in men. Its chemical structure includes N-arylhydroxyalkyl. A phase one trial found promising results.[1][2]
References
- ↑ Krishnan, V.; Patel, N. J.; Mackrell, J. G.; Sweetana, S. A.; Bullock, H.; Ma, Y. L.; Waterhouse, T. H.; Yaden, B. C.; Henck, J.; Zeng, Q. Q.; Gavardinas, K.; Jadhav, P.; Saeed, A.; Garcia-Losada, P.; Robins, D. A.; Benson, C. T. (2018). "Development of a selective androgen receptor modulator for transdermal use in hypogonadal patients". Andrology. 6 (3): 455–464. doi:10.1111/andr.12479.
- ↑ Christiansen, Andrew R.; Lipshultz, Larry I.; Hotaling, James M.; Pastuszak, Alexander W. (March 2020). "Selective androgen receptor modulators: the future of androgen therapy?". Translational Andrology and Urology. 9 (Suppl 2): S135–S148. doi:10.21037/tau.2019.11.02. ISSN 2223-4683. PMC 7108998. PMID 32257854.
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.